The link between diabetes and neurodegenerative diseases is increasingly evident, revealing shared 
underlying mechanisms such as inflammation and disrupted insulin pathways.  Insulin-degrading enzyme (IDE) emerges as a potential therapeutic target for addressing both conditions simultaneously.

​​

Diabetes, particularly type 2, involves insulin resistance and impaired glucose metabolism, impacting the brain and increasing the risk of neurodegenerative diseases like Alzheimer’s, Parkinson’s, and vascular dementia.  Common factors such as inflammation, oxidative stress, and vascular dysfunction contribute to the development of both diabetes and neurodegeneration. Additionally, insulin resistance disrupts crucial brain processes and diabetes-related vascular issues worsen neuronal damage. 

​

Our study focuses on IDE inhibition, examining antibodies A9 and H3 for their interactions with IDE, with H3 demonstrating inhibitory effects on IDE enzymatic activity.  IDE, acting as a protease, plays a crucial role in degrading insulin and amyloid beta peptides, thus regulating their levels in the body.

 

The research combines computational analyses and experimental assays to explore the structural and functional aspects of IDE binding by H3, aiming to improve its inhibitory properties. 

By advancing our understanding of IDE inhibition and its therapeutic potential, this research holds promise for transforming the landscape of diabetes and neurodegenerative disease treatment, offering hope for improved outcomes and enhanced quality of life for millions worldwide.